Adverum Biotechnologies
ADVM
ADVM was delisted on the 8th of December, 2025.
63 hedge funds and large institutions have $32.5M invested in Adverum Biotechnologies in 2017 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 17 increasing their positions, 19 reducing their positions, and 20 closing their positions.
1.79% less ownership
Funds ownership: 32.15% → 30.36% (-1.8%)
11% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 19
11% less capital invested
Capital invested by funds: $36.5M → $32.5M (-$3.98M)
16% less funds holding
Funds holding: 75 → 63 (-12)
55% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 20
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $13K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$5.47M |
| 2 |
Millennium Management
New York
|
+$818K |
| 3 |
Renaissance Technologies
New York
|
+$771K |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$551K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$535K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.92M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.63M |
| 3 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$1.45M |
| 4 |
CC
Casdin Capital
New York
|
-$1.13M |
| 5 |
State Street
Boston,
Massachusetts
|
-$899K |
ADVM Hedge Fund Activity: Q2 2017 in Review
63 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q2 2017, worth a combined $32.5M — down 11% from $36.5M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of ADVM and 9 opened new positions — a net loss of 11 holders — while 19 trimmed existing stakes and 17 added.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $5.47M. The largest seller was BlackRock, cutting an estimated $2.92M.
- 63 institutional investors held Adverum Biotechnologies (ADVM) as of Q2 2017, down from 75 in Q1 2017.
- Funds reported $32.5M of Adverum Biotechnologies stock for Q2 2017, down 11% quarter-over-quarter.
- 9 funds opened new Adverum Biotechnologies positions in Q2 2017 and 20 closed out, a net change of -11 holders.
- The largest Adverum Biotechnologies buyer in Q2 2017 was Adage Capital Partners, an estimated $5.47M added.
- The largest Adverum Biotechnologies seller in Q2 2017 was BlackRock, an estimated $2.92M sold.
Based on aggregated 13F filings for Q2 2017.